Authors: | Tremblay, C. L.; Giguel, F.; Guan, Y.; Chou, T. C.; Takashima, K.; Hirsch, M. S. |
Article Title: | TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals in vitro |
Abstract: | TAK-220 is a CCR5 antagonist, part of the new class of anti-human immunodeficiency virus type 1 (anti-HIV-1) entry inhibitors. We evaluated the anti-HIV-1 interactions between TAK-220 and various anti-retrovirals in vitro. Synergy was observed with all drugs at the 90 and 95% inhibitory concentrations. The favorable drug interactions observed suggest that further clinical evaluation is warranted. Copyright © 2005, American Society for Microbiology. All Rights Reserved. |
Keywords: | controlled study; unclassified drug; human cell; drug activity; drug potentiation; nonhuman; enzyme inhibition; in vitro study; drug receptor binding; drug synergism; leukocytes, mononuclear; antiretrovirus agent; anti-hiv agents; hiv infections; peripheral blood mononuclear cell; human immunodeficiency virus 1; hiv-1; zidovudine; lamivudine; indinavir; minimum inhibitory concentration; anti human immunodeficiency virus agent; chemokine receptor ccr5; efavirenz; receptors, ccr5; enfuvirtide; 1 acetyl n [3 [4 (4 carbamoylbenzyl) 1 piperidinyl]propyl] n (3 chloro 4 methylphenyl) 4 piperidinecarboxamide; reverse transcriptase inhibitors |
Journal Title: | Antimicrobial Agents and Chemotherapy |
Volume: | 49 |
Issue: | 8 |
ISSN: | 0066-4804 |
Publisher: | American Society for Microbiology |
Date Published: | 2005-08-01 |
Start Page: | 3483 |
End Page: | 3485 |
Language: | English |
DOI: | 10.1128/aac.49.8.3483-3485.2005 |
PUBMED: | 16048964 |
PROVIDER: | scopus |
PMCID: | PMC1196290 |
DOI/URL: | |
Notes: | --- - "Cited By (since 1996): 21" - "Export Date: 24 October 2012" - "CODEN: AMACC" - "Source: Scopus" |